LOXL2 and nonpapillary renal cell carcinoma: In ccRCC, lysyl oxidase-like-2 (LOXL2) induces metastatic changes, such as epithelial-to-mesenchymal transition (EMT), through the steroid receptor coactivator (Src)/FAK signaling pathway.